Aarti Drugs will grow and the stock is cheap
The Indian pharma sector comprises a diverse set of players. There are somnolent multinationals, dictated by the policies of their remote parents. The larger Indian ones, like Dr Reddy’s and Ranbaxy, have tried to go down the path of patent challenges but got entangled in litigation launched by US pharma companies. Smaller and medium-sized Indian...
In my 25 years of writing and reporting, if there is one common shortcoming I have found among business people, it is ignorance of history. Among industrialists, this ignorance manifests in their bafflement when the business cycle turns down. The steel barons were as unprepared in 2008 with falling demand and increased supply as they were in 1994. In the last three market peaks (1994, 2000 and...
What has highly complex intensive-care medicine got to do with investing? Shreedhar Kanetkar explains
It has become commonplace in recent years to describe the world economy as an aircraft powered by two engines -- the United States and China. Occasionally, it can be instructive to ask: how difficult is it, really, to keep an aircraft in the air?
Some insight can be gleaned from a...
